

NEWS RELEASE

DELMEDICAINVESTMENTS October 2008



Delmedica offers the private equity investor access to unique biotechnology opportunities that have the hallmarks of commercially successful ventures.



Delmedica attended the European Respiratory Society meeting in Berlin from 4-8th October where we launched the X-halo, the world's first medical device that measures the temperature of the exhaled breath, predicting the onset of an asthma attack, viral infections and bacterial infections. 18,500 pulmonary specialists from all over the world attended the meeting.

Delmedica was exhibiting the only new technology and we generated enormous interest and discussion.

Our aim is to encourage researchers, Pharmaceutical companies and clinicians to utilise X-Halo in numerous clinical trials. This will generate further published clinical work, in addition to the completed, on-going and soon to be commissioned studies co-ordinated by Delmedica.

- This will position X-Halo in the market place with the support of numerous researchers and with supporting clinical evidence. In conjunction with selected distributors of medical respiratory equipment launch of X-Halo to the general public is being planned for the 2nd and 3rd quarter next year. Actions to CE mark and achieve FDA device approval have been instigated, and it is expected that CE mark should be approved by year end and the FDA by end Q1 2009

Some of the highlights of the meeting are summarized below:

- A substantial number of the 17,000 delegates and other exhibitors visited our stand over the 3 and a half days of the show
- All Visitors were scanned who attended our stand and given materials and copies of clinical studies, most requested a demonstration of the product and wanted documentation and further information.
- All the units we took to the show were sold at the show itself and further orders have been placed through the web site ordering system.
- Distributors from the Benelux, Scandinavia, Lithuania, Georgia, Romania, Portugal, Italy, Germany, Spain, Australia, Greece, UK and Ireland, India, the US and Taiwan all showed considerable interest in marketing the device in their respective countries. Discussions are currently on-going to further develop these leads.
- Prof.G.Piacentini, one of the leading researchers in exhaled breath temperature work, visited the stand and was so impressed with the device that he has decided to collaborate with us and use our device in his upcoming studies.
- Dr.Paolo Chiesi (head R&D Chiesi Pharma, one of the largest Italian pharmaceutical companies) visited the stand and expressed interest to purchase some devices and also to carry out some further studies using the device, a number of other pharmaceutical companies requested information to use devices in their clinical trials and well as CRO companies (Clinical trial organizers)
- Further work to evaluate the device in the field of exercise induced asthma in elite athletes has been agreed in collaboration with world recognized specialists in this field, in Norway, Sweden, USA, Italy and other countries.
- Our Scientific team displayed a poster entitled "Ability of an individual device for measurement of the temperature of exhaled breath to detect changes in patients recovering from mild exacerbations of asthma" which was very well received
- A publication entitled "Exhaled Breath Temperature Measurement Made Easy" by T.Popov et al has been accepted for publication in the "Journal of Pediatric Allergy and Immunology"

DELMEDICA

7 Temasek Boulevard, #06-01, Suntec Tower 1, Singapore 038987

www.delmedicainvestments.com